Primary results of phase 3 AURIGA study indicated that dual maintenance therapy after transplant led to improved outcomes.

In this article, Cerba dives into CAR+ T-cell therapy, from patient treatment to solutions for minimal residual disease (MRD) ...

The phase 3 AURIGA study evaluated daratumumab (Darzalex) and lenalidomide vs lenalidomide maintenance in patients with newly diagnosed multiple myeloma who were in very good partial response, minimal ...

demonstrated that daratumumab, a monoclonal antibody that targets CD38, a protein found on the surface of myeloma cells, significantly reduces the risk of progression to active multiple myeloma ...

Panelists discuss how the IMROZ trial demonstrated improved outcomes with quadruplet therapy combining daratumumab, lenalidomide, melphalan, and prednisone in patients with transplant-ineligible newly ...

demonstrated that daratumumab, a monoclonal antibody that targets CD38, a protein found on the surface of myeloma cells, significantly reduces the risk of progression to active multiple myeloma ...

It joins a number of other BCMA-directed therapies for multiple myeloma ... generated anti-CD38 blockbuster Darzalex (daratumumab). Talquetamab has also shown promise in myeloma in the phase ...

GSK continues to build the case for its multiple myeloma therapy Blenrep ... Johnson’s $10 billion-a-year anti-CD38 antibody Darzalex (daratumumab) with PomDex in the head-to-head DREAMM ...

Previously we used to use Anti-CD38 ... myeloma also include the use of PCMA based therapy. BCMA is B-cell maturation antigen and it is a way for us to target the myeloma cell. So there are ...

Daratumumab, hyaluronidase-fihj ... a polysaccharide found in the extracellular matrix. Treatment of multiple myeloma: in combination with bortezomib, lenalidomide, and dexamethasone for induction ...